Apotex reports $38M net loss in first quarter after going public in June
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
TORONTO – Apotex Health Corp. says it had a net loss of $38.3 million in its first quarter as its revenue fell from the same period last year.
The pharmaceutical company says the result compared with a profit of $362.7 million in last year’s first quarter.
That amounted to a diluted loss per share of 19 cents during the quarter ended June 30, compared with diluted earnings per share of $1.88 a year ago.
Apotex says its revenue reached $848 million during the quarter, down year-over-year from $1.14 billion.
After 52 years as a private company, Apotex announced on June 16 that it closed its upsized IPO at a price of $24 per share for gross proceeds of nearly $1.5 billion.
Its chief executive Jeff Watson said the money raised from the IPO can be used to reduce debt and provide more flexibility on Apotex’s balance sheet.
This report by The Canadian Press was first published Aug. 12, 2026.
Companies in this story: (TSX:APTX)